Addex Therapeutics Ltd/ CH0029850754 /
2024-04-04 5:19:18 PM | Chg. - | Volume | Bid9:01:01 AM | Ask9:01:01 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
0.126CHF | - | 30,992 Turnover: 4,131.174 |
-Bid Size: - | -Ask Size: - | 11.31 mill.CHF | - | - |
GlobeNewswire
7:00 AM
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
04-11
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire
04-03
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire
01-31
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire
2023-11-23
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
GlobeNewswire
2023-09-06
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
2023-09-04
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
GlobeNewswire
2022-03-24
Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences
GlobeNewswire
2022-03-10
Addex Reports Full Year 2021 Financial Results and Provides Corporate Update
GlobeNewswire
2022-03-07
Addex Therapeutics to Release Full-Year 2021 Financial Results and Host Conference Call on March 10,...